• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Nang Kuang`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Eugia`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Kindos` Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Apotex`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Eugia Pharma`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States

    PR NEWSWIRE

    Eagle Pharma Reaches Settlement Agreement with Dr. Reddy`s Laboratories Inc.

    GLOBENEWSWIRE

    Eugia`s Generic Bendamustine Hydrochloride Hydrate Receives Approval in the U.S.

    FDA

    Eagle Pharma Reaches Settlement Agreement with Accord Related to BENDEKAÂ

    GLOBENEWSWIRE

    Accord`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Dr. Reddy`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    Health Canada Issues Recall of Natco Pharma (Canada) Inc NAT-Bendamustine

    HEALTH CANADA

    Breckenridge`s Generic Bendamustine Hydrochloride Receives Approval in the U.S.

    FDA

    NICE signs off on BeiGene`s Brukinsa for blood cancer disorder

    FIERCEPHARMA

    Eagle Reaches Settlement Agreement with Hospira Related to BENDEKA

    GLOBENEWSWIRE

    BeiGene Presents Results from SEQUOIA Trial of BRUKINSA in CLL

    BUSINESSWIRE

    MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study

    BUSINESSWIRE

    BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia

    BUSINESSWIRE

    Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

    BUSINESSWIRE

    Oncopeptides presents new clinical & preclinical melflufen data at EHA meeting

    PRNEWSWIRE

    Eagle Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation

    BUSINESSWIRE

    Bendamustine : increased risk of non-melanoma skin cancer and progressive

    GOVUK

    Apotex`s Generic Bendamustine Hydrochloride Receives Tentative Approval in US

    FDA

    Accord Hlthcare`s Generic Bendamustine HCl Receives Tentative Approval In US

    FDA

    Teva moves US court against Aurobindo Pharma on cancer drug Bendeka

    THEHINDUBUSINESSLINE

    Teva’s cancer drug Bendeka protected from generics until 2031, judge rules

    PHARMAFILE

    Court Issues Favorable Patent Litigation Decision for Eagle & Teva Pharma

    BIOSPACE

    Teva Wins Ruling on Patents for Bendeka Cancer Drug

    BLOOMBERG

    Court Issues Favorable Patent Litigation Decision for Eagle Pharma & Teva Pharma

    BUSINESSWIRE

    Nanjing King-Friend`s Generic Bendamustine Hydrochloride Receives Tentative Approval in US

    FDA

    Eagle Pharma’s Japanese Licensing Partner SymBio Announces Completion TREAKISYM

    BUSINESSWIRE

    ADC Therapeutics Rakes in $303 Million with Addition to its Series E

    BIOSPACE

    AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition

    BIOSPACE

    AstraZeneca`s Calquence sets Imbruvica in its sights

    FIERCE PHARMA

    Roche touts phase 2 Gazyva data in lupus patients

    FIERCE PHARMA

    Roche snags first-in-class FDA nod for lymphoma drug Polivy

    FIERCE PHARMA

    AZ`s Calquence chases Imbruvica with phase 3 leukemia win

    FIERCE PHARMA

    Treanda copycat delay shows FDA trapped by orphan drug rules

    FIERCE PHARMA

    Additional Exclusivity for a Cancer Treatment Could Cost the Public $3 Billion

    RAPS

    Additional exclusivity for a cancer treatment could cost the public $3 billion

    ENDPTS

    Accord Healthcare`s Generic Bendamustine Hydrochloride Receives Tentative Approval in US

    FDA

    Breckenridge Pharm`s Generic Bendamustine Hydrochloride Receives Tentative Approval in US

    FDA

    Mylan`s Generic Bendamustine Hydrochloride Receives Tentative Approval in US

    FDA

    Glenmark Pharm`s Generic Bendamustine Hydrochloride Receives Tentative Approval in US

    FDA

    Pharmascience`s Generic Bendamustine Hydrochloride Receives Tentative  in US

    FDA

    Bendamustine Hydrochloride Injection : Eagle Pharmaceuticals vs. Slayback Pharma

    PATENT LITIGATION

    Imbruvica (ibrutinib): Pharmacyclics, Janssen Biotech vs. Hetero Labs

    PATENT LITIGATION

    Roche announces EU approval of Venclyxto plus MabThera for CLL

    GLOBENEWSWIRE

    Bendeka (bendamustine hydrochloride) : Teva Pharma, Cephalon vs. Eagle Pharma

    PATENT LITIGATION

    Bendamustine Hydrochloride Injection : Eagle Pharmaceuticals vs. Slayback Pharma

    PATENT LITIGATION

    FDA Confirms Paragraph IV Patent Challenge of Bendamustine Hydrochlride 205580 Injection

    FDA

    BENDEKA® (bendamustine HCl) Injection: Eagle Pharma et al v. Hospira, Inc.

    PATENT LITIGATION

    FDA Grants Eagle 7Y Orphan Drug Exclusivity for bendamustine HCl injection

    BUSINESSWIRE

    Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

    BUSINESSWIRE

    YiChang Humanwell`s Generic Bendamustine Hydrochloride Receives Tentative Approval In US

    FDA

    Hospira’s Generic Bendamustine Hydrochloride Receives Tentative Approval In US

    FDA

    Innopharma`s Generic Bendamustine Hydrochloride Receives Tentative Approval In US

    FDA

    Genmab/Novatis’ Arzerra fails to hit NHL targets

    PHARMA TIMES

    Enforcement Report - Week of May 16, 2018

    FDA

    Mylan Lab`s Generic Bendamustine Hydrochloride Receives Approval In US

    FDA

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.